When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
OGEN - Oragenics And AGO13 In Severe Oral Mucositis
Oragenics Inc.
Clinical Differentiation And Gap
Oragenics Inc. (OGEN) is a small-cap ($21M) clinical-stage company developing innovative therapies for SOM and infectious diseases. Focusing on SOM associated with head and neck cancer (HNC.) radiotherapy, Phase 2 investigative drug candidate AGO13 was in-licensed from Intrexon (XON) in 2015.
In the US, ~500,000 individuals are diagnosed with OM annually and the prevalence is expected to rise in parallel with an increasing incidence of HNC projected at 65,000 every year. The annual addressable market for oral mucositis in G8 countries was estimated to be $638.8M in